ASCO 2012: 难治性SCLC:阿柏西普有潜力(SWOG 0802研究)
2012-06-17 范泽玲 医学论坛网
一项Ⅱ期临床试验表明,一种新型血管内皮生长因子(VEGF)阻滞剂可延缓铂类耐药小细胞肺癌(SCLC)的进展速度。 美国田纳西大学的Jeffrey Warren Allen博士和同事们发现,与单纯托泊替康治疗相比,联合阿柏西普可提高患者3个月无进展生存(PFS)率(27% 对 10%,P=0.01)。 他们在2012年美国临床肿瘤学会年会(ASCO 2012)上报告,患者总生存和缓解率未得到提高,但
一项Ⅱ期临床试验表明,一种新型血管内皮生长因子(VEGF)阻滞剂可延缓铂类耐药小细胞肺癌(SCLC)的进展速度。
美国田纳西大学的Jeffrey Warren Allen博士和同事们发现,与单纯托泊替康治疗相比,联合阿柏西普可提高患者3个月无进展生存(PFS)率(27% 对 10%,P=0.01)。
他们在2012年美国临床肿瘤学会年会(ASCO 2012)上报告,患者总生存和缓解率未得到提高,但毒性反应小。
“有必要在该患者群体中进一步研究托泊替康和阿柏西普的效果,”Allen说。
作为研究者之一的美国加利福尼亚大学戴维斯综合肿瘤中心的David R. Gandara博士指出,托泊替康是唯一获准用于SCLC二线治疗的药物,主要对仍对铂类敏感的患者有效。
“在二线治疗中,如果患者仍对铂类敏感,则许多化疗药物有效,但是若患者对铂类耐药则疗效较差,”他解释说。
为对铂类为基础化疗耐药的SCLC患者探索新的治疗选择迫在眉睫,但很多靶向药物都失败了,他指出。
阿柏西普是一种重组人融合蛋白,与循环VEGF紧密结合,使其不能与细胞表面受体相互作用。
Allen等共报告了98例可评估的铂类耐药、广泛期或局限期SCLC患者,随机给予其单纯托泊替康(4 mg/m2静脉注射,第1、8和15日给药)或联合阿柏西普(6 mg/kg静脉注射,第1日给药)治疗。
该研究还纳入了铂类敏感队列,但本次报告时尚未分析该队列。
托泊替康标准给药方案是每个周期连续5日每日给药,但研究者选择了每周给药方案以减轻毒性反应。
联合阿柏西普治疗组3个月无进展生存率显著高于单纯托泊替康治疗组,但两组的中位PFS均为1.4个月。
联合治疗组和单纯托泊替康组的总生存期也无显著差异(4.6个月 对 4.2个月,P=0.35)。
研究中罕见肿瘤缩小。单纯托泊替康组未出现客观缓解,阿柏西普组客观缓解率仅为2%。
但是,“抗血管生成药物可能会在实体瘤疗效评价标准(RECIST)未显示缓解的情况下已经显示生物学活性,”Gandara指出。
阿柏西普和托泊替康联合治疗组毒性反应主要为血液学毒性。联合治疗组和单纯治疗组出现3级毒性事件的患者例数分别为20和15例,出现4级毒性事件的例数分别为8和5例。
标题:SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC).(Abstract 7005)
作者:Jeffrey Warren Allen, James Moon, Shirish M. Gadgeel, Karen Kelly,et al.
英文摘要:
Background: Topotecan (T) (oral and IV) is the only FDA-approved second-line chemotherapy for patients with SCLC. Weekly T is associated with less toxicity than the daily x 5 regimen. AVE0005 (aflibercept) (A) is a novel recombinant human fusion protein which binds to circulating VEGF, thereby inhibiting its interaction with cell surface receptors. We sought to evaluate the efficacy and toxicity of weekly IV T (4 mg/m2) with or without A (6 mg/kg Q21D) in patients with relapsed SCLC following one line of platinum-based chemotherapy for E or limited-stage (L) SCLC.
Methods: Patients were randomized 1:1 to T or A+T. Eligible patients had adequate organ function, ECOG PS 0-1, and no recent bleeding or cardiac events. Patients with brain metastases stable for ≥ 3 months prior to study entry were allowed. Primary endpoint was 3-month PFS. Patients were stratified as platinum-sensitive (PS) or platinum-refractory (PR). PR patients had progressed within 90 days of last chemotherapy for E and 6 months for L. This report is limited to the PR stratum.
Results: 98 patients were registered. 1 was ineligible and 1 withdrew consent, leaving 96 evaluable for the primary endpoint (91 for toxicity (see Table for characteristics)). 3-month PFS was 26% for A+T versus 9% for T (P=0.01). Overall survival was similar in each arm (4.6 mos (A+T) versus 3.9 mos (T) (P=0.25)). There was 1 partial response with A+T. Disease control rate (DCR) was 28% with A+T and 12% with T. Toxicity was mainly hematologic with 14% and 19% of patients experiencing a Grade 4 event with T and A+T, respectively. There was one treatment-related death with T (renal failure).
Conclusions: This study met its primary endpoint of improved 3-month PFS with A+T (p=0.01), warranting further study in the PR setting. Clinical benefit with A+T was achieved primarily through improved DCR. Toxicity was manageable and less than is seen with standard dose T. Accrual to the PS cohort is ongoing.
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
#ASC#
81
#阿柏西普#
60
#难治性#
54